Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gibbons

Showing results (271-280 of 523) with videos related to

Pageof 53
Sort By:
Nature Communications|May 11, 2021
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancersDavid H Peng, B Leticia Rodriguez, Lixia Diao, et al.
British Journal of Cancer|October 5, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancerBenjamin C Creelan, Tammie C Yeh, Sang-We Kim, et al.
Cancer Immunology Research|February 25, 2026
Loss of miR-29a/b1 cluster reprograms the tumor microenvironment and contributes to immunosuppression in lung cancerNatalie K Horvat, Myritney Saint-Cloud, Raihaanah Bint Abdullah Muslim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2023
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancerH T Tran, S Heeke, S Sujit, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2006
The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in malesR Srinivasan, Y Davidson, L Gibbons, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Multi-Drug Resistant <i>Staphylococcus aureus</i> Carriage in Abattoir Workers in Busia, KenyaBenear Apollo Obanda, Cheryl L Gibbons, Eric M Fèvre, et al.
Cancer Research|January 6, 2021
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLCJessica M Konen, B Leticia Rodriguez, Aparna Padhye, et al.
Cell Reports|September 28, 2022
Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasisRakhee Bajaj, B Leticia Rodriguez, William K Russell, et al.
Clinical Lung Cancer|February 26, 2022
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung CancerMehmet Altan, Eric K Singhi, Michelle Worst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2016
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung AdenocarcinomaYanyan Lou, Lixia Diao, Edwin Roger Parra Cuentas, et al.
Pageof 53

Showing results (271-280 of 523) with videos related to

Sort By:
Pageof 53
Nature Communications|May 11, 2021
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancersDavid H Peng, B Leticia Rodriguez, Lixia Diao, et al.
British Journal of Cancer|October 5, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancerBenjamin C Creelan, Tammie C Yeh, Sang-We Kim, et al.
Cancer Immunology Research|February 25, 2026
Loss of miR-29a/b1 cluster reprograms the tumor microenvironment and contributes to immunosuppression in lung cancerNatalie K Horvat, Myritney Saint-Cloud, Raihaanah Bint Abdullah Muslim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2023
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancerH T Tran, S Heeke, S Sujit, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2006
The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in malesR Srinivasan, Y Davidson, L Gibbons, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Multi-Drug Resistant <i>Staphylococcus aureus</i> Carriage in Abattoir Workers in Busia, KenyaBenear Apollo Obanda, Cheryl L Gibbons, Eric M Fèvre, et al.
Cancer Research|January 6, 2021
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLCJessica M Konen, B Leticia Rodriguez, Aparna Padhye, et al.
Cell Reports|September 28, 2022
Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasisRakhee Bajaj, B Leticia Rodriguez, William K Russell, et al.
Clinical Lung Cancer|February 26, 2022
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung CancerMehmet Altan, Eric K Singhi, Michelle Worst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2016
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung AdenocarcinomaYanyan Lou, Lixia Diao, Edwin Roger Parra Cuentas, et al.
Pageof 53